Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

BACKGROUND: Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly patients. The addition of bevacizumab to docetaxel seems promising; however, the feasibility of this combination has not been investigated in such patients. METHODS: Patients with advanced n...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Takagi, Yusuke, Hosomi, Yukio, Oshita, Fumihiro, Okamoto, Hiroaki, Seki, Nobuhiko, Minato, Koichi, Aono, Hiromi, Yamada, Kouzo, Okuma, Yusuke, Hida, Naoya, Sakamoto, Takahiko, Miura, Yosuke, Yomota, Makiko, Satoh, Akira, Kunitoh, Hideo, Sakamaki, Kentaro, Shibuya, Masahiko, Watanabe, Koshiro
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2015
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4612532/
https://ncbi.nlm.nih.gov/pubmed/26481215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1756-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים